Expansion of research and mentoring opportunities to reduce the burden of maternal and pediatric HIV in Botswana

扩大研究和指导机会，以减轻博茨瓦纳孕产妇和儿童艾滋病毒负担

• 批准号: 10762238
• 负责人: Roger L Shapiro
• 金额: $ 18.78万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-05 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10762238
• 关键词: Acquired Immunodeficiency Syndrome; Adolescent; Africa; Award; Birth; Boston; Botswana; COVID-19; Caregivers; Caring; Cesarean section; Characteristics; Child; Childhood; Clinical Data; Clinical Trials; Communicable Diseases; DNA; Data; Data Collection; Data Set; Databases; Diagnostic; Education; Eligibility Determination; Exclusion; Factor Analysis; Faculty; Financial Support; Fostering; Funding; Future; Goals; Government; Guidelines; HIV; High Risk Woman; Hospitals; Immunologics; Incidence; Individual; Infant; Injectable; Interruption; Intervention; Interview; Laboratories; Length; Link; Maternal Mortality; Maternal-fetal medicine; Measurable; Medical; Mentors; Mentorship; Mothers; Outcome; Participant; Perinatal; Postdoctoral Fellow; Pregnancy; Provider; Qualifying; Regimen; Research; Research Activity; Research Personnel; Research Support; Risk; Risk Factors; Safety; Site; Specimen; Standardization; Structure; Students; Testing; Time; Training; Travel; United States; United States National Institutes of Health; Vertical Transmission; Virus; Visit; Woman; Work; adverse birth outcomes; career; cohort; data sharing; delivery complications; early childhood; global health; high risk infant; improved; intrapartum; maternal morbidity; medical complication; next generation; novel; patient oriented; patient oriented research; pediatric human immunodeficiency virus; pre-exposure prophylaxis; pregnant; programs; surveillance study; testing uptake; tool; treatment program; treatment strategy; uptake

Summary / Abstract I am applying for a K24 renewal with the goal of expanding the scope of my NIH-funded research and expanding mentorship opportunities at the Botswana-Harvard AIDS Institute Partnership in Botswana. In the past 23 years, I have built a successful research program in Botswana with a recent focus on adverse birth outcomes surveillance and novel treatment strategies for children with HIV. I have successfully mentored or co-mentored nearly 50 young investigators in my career, and my current K24 has been essential for my recent mentoring activities. Despite the challenges of COVID-19, my K24 research and mentoring aims have been achieved – and often expanded – over the past 5 years. With re-funding, my K24-supported research will have the following mentored research aims, which span all of my funded research activities: (1) to evaluate uptake of 6-week HIV DNA PCR testing, risk factors for lack of testing, and risk factors for HIV vertical transmission in the Botswana national treatment program; (2) to evaluate the uptake of cabotegravir-LA pre-exposure prophylaxis (PrEP) offered in pregnancy through the Botswana national program; (3) to determine the incidence of maternal morbidity and mortality associated with cesarean section at Princess Marina Hospital (by HIV status), and develop interventions to standardize medical indications for caesarean section, while training my current mentee to become a mentor; and (4) to perform specialized diagnostics and qualitative interviews to optimize a strategy for a future analytic treatment interruption (ATI) among highly selected children and adolescents living with HIV, while fostering research independence in a Botswana-based laboratory mentee. My training plan will specifically expand my expertise in maternal-fetal medicine and HIV cure strategies, and my mentoring plan will involve a team approach with co-mentors in Boston and Botswana to efficiently utilize opportunities within a new Program Award, ongoing clinical trials, and existing datasets and specimens. The ultimate goal of my K24 renewal application is to expand capacity to conduct high-impact patient-oriented research in Botswana by the next generation of global health leaders from Africa and the United States.

摘要/摘要

项目成果

Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.

博茨瓦纳替诺福韦-恩曲他滨-依非韦伦起始妊娠年龄对不良出生结局的影响。

• DOI: 10.1093/jpids/piy006
• 发表时间: 2018
• 期刊: Journal of the Pediatric Infectious Diseases Society
• 影响因子: 3.2
• 作者: Zash,Rebecca;Rough,Kathryn;Jacobson,DeniseL;Diseko,Modiegi;Mayondi,Gloria;Mmalane,Mompati;Essex,Max;Petlo,Chipo;Lockman,Shahin;Makhema,Joseph;Shapiro,RogerL
• 通讯作者: Shapiro,RogerL

Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana.

• DOI: 10.4102/sajhivmed.v19i1.751
• 发表时间: 2018
• 期刊: Southern African journal of HIV medicine
• 影响因子: 1.7
• 作者: Powis KM;Lockman S;Ajibola G;Hughes MD;Bennett K;Leidner J;Batlang O;Botebele K;Moyo S;van Widenfelt E;Makhema J;Petlo C;Jibril HB;McIntosh K;Essex M;Shapiro RL
• 通讯作者: Shapiro RL

No increased in utero and peripartum HIV acquisition risk in HIV-exposed preterm infants.

• DOI: 10.4102/sajhivmed.v24i1.1509
• 发表时间: 2023
• 期刊: Southern African journal of HIV medicine
• 影响因子: 1.7
• 作者: Ajibola G;Mdluli C;Bennett K;Sakoi M;Batlang O;Makhema J;Lockman S;Shapiro R;Myer L;Powis K
• 通讯作者: Powis K

Rapid dynamic changes of FL.2 variant: A case report of COVID-19 breakthrough infection.

• DOI: 10.1016/j.ijid.2023.11.011
• 发表时间: 2024-01
• 期刊: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
• 影响因子: 8.4
• 作者: Choga, Wonderful T.;Kurusa (Gasenna), Gobuiwang Khilly;San, James Emmanuel;Ookame, Tidimalo;Gobe, Irene;Chand, Mohammed;Phafane, Badisa;Seru, Kedumetse;Matshosi, Patience;Zuze, Boitumelo;Ndlovu, Nokuthula;Matsuru, Teko;Maruapula, Dorcas;Bareng, Ontlametse T.;Macheke, Kutlo;Kuate-Lere, Lesego;Tlale, Labapotswe;Lesetedi, Onalethata;Tau, Modiri;Mbulawa, Mpaphi B.;Smith-Lawrence, Pamela;Matshaba, Mogomotsi;Shapiro, Roger;Makhema, Joseph;Martin, Darren P.;de Oliveira, Tulio;Lessells, Richard J.;Lockman, Shahin;Gaseitsiwe, Simani;Moyo, Sikhulile
• 通讯作者: Moyo, Sikhulile

Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.

• DOI: 10.1097/qad.0000000000001673
• 发表时间: 2018-01-02
• 期刊: AIDS (London, England)
• 作者: Caniglia EC;Zash R;Jacobson DL;Diseko M;Mayondi G;Lockman S;Chen JY;Mmalane M;Makhema J;Hernán MA;Shapiro RL
• 通讯作者: Shapiro RL